Survival from childhood cancer has improved considerably over the last few decades, and currently nearly 80% of children diagnosed with cancer survive at least five years ([@djx056-B1]). This dramatic improvement in survival is mainly attributable to advances in multimodality therapy with combination chemotherapy and improved radiotherapy delivery. However, various studies have shown that previous cancer treatment, particularly following radiotherapy, increases the long-term risk of developing adverse health outcomes, including second primary cancer, cardiovascular disease, infertility, and adverse pregnancy outcomes ([@djx056-B2],[@djx056-B3]).

Female survivors of childhood cancer who have been treated with abdominal radiotherapy and who subsequently managed to conceive are at risk of premature delivery and delivering low-birthweight offspring ([@djx056-B4]). The exact mechanism underlying this risk is not entirely clear, but it has been postulated that exposure to abdominal irradiation increases myometrial fibrosis and negatively affects vascular and/or muscular development of the uterus ([@djx056-B11],[@djx056-B12]). Although the risks of premature delivery and delivering low-birthweight offspring in survivors of childhood cancer are well documented ([@djx056-B4]), it is unclear whether previous treatment with abdominal radiotherapy for childhood cancer may also be associated with additional complications during pregnancy and labor. Green et al. ([@djx056-B5],[@djx056-B13]) reported that female survivors of unilateral Wilms' tumor treated with flank irradiation are at risk of fetal malposition, early or threatened labor, and developing hypertension complicating pregnancy, but to the best of our knowledge, no other large-scale study has investigated the risk of specific pregnancy and labor complications in women treated with abdominal radiotherapy for childhood cancer.

The principal aim of this study was to investigate the risks of developing pregnancy and labor complications ascertained through linkage with hospital electronic health records in female survivors treated with abdominal radiotherapy for childhood cancer.

Methods
=======

British Childhood Cancer Survivor Study
---------------------------------------

The British Childhood Cancer Survivor Study is a large-scale population-based cohort of 17 980 five-year survivors of childhood cancer who were diagnosed with cancer between age 0 to 14 years from 1940 to 1991 in Britain ([@djx056-B14]). The cohort was ascertained through the National Registry of Childhood Tumours. The BCCSS cohort was linked to the population-based Hospital Episode Statistics (HES) for England---an electronic database that records data on patients' hospital admissions (inpatient), outpatient appointments, and accident and emergency attendances at National Health Service (NHS) or private hospitals (if care was commissioned by the NHS). HES is managed by NHS digital and developed as a system for hospitals to get paid for administered patient care. For this study, the BCCSS cohort was linked to the inpatient HES data set from April 1, 1997, to December 31, 2012, by a third party (Northgate Solutions) using NHS number, date of birth, and postcode. Approval to link the BCCSS cohort to HES without prior individual patient consent was obtained from the Confidentiality Advisory Group and the National Research Ethics Service.

As HES only covers England, 2116 (11.8%) five-year survivors who were alive and residing in Scotland or Wales were excluded from analyses. Among the 6192 female survivors in the cohort who were alive as of April 1, 1997, 5126 (82.8%) had at least one recorded hospital admission in the HES inpatient data set.

The HES inpatient data set includes any records relating to care given for births that took place in NHS hospitals. Although home deliveries and births in private hospitals should be recorded in HES, practically few are ([@djx056-B15]), and hence these deliveries were excluded (n = 35). Pregnancies that resulted in a multiple birth (n = 85) were also excluded as the risk of pregnancy and labor outcomes is likely to differ from singleton births.

For comparisons with the general population, a random sample of 25 000 deliveries was extracted from the entire (anonymized) HES database (n = 8 821 531 deliveries). A sample of 25 000 was decided upon because at that size the sample was sufficiently large to provide ample statistical power, and, moreover, larger samples (eg, n = 100 000) resulted in similar results (results not shown).

Pregnancy and Labor Complications
---------------------------------

Pregnancy and labor complications were only evaluated if there were at least 50 affected pregnancies. Medical conditions and complications are recorded in HES using the *International Classification of Diseases* (ICD), revision 10. Specifically, we investigated the risk of: hypertension complicating pregnancy (ICD-10: O10-O11/O13-O16), gestational diabetes mellitus (O24.4), anemia complicating pregnancy (O99.0), malpresentation of fetus (O32), maternal care due to uterine scar from previous surgery (O34.2), fetal problems (O36), premature rupture of membranes (ie, rupture of the amniotic sac; O42), prolonged pregnancy (O48), abnormalities of forces of labor (O62), long labor (O63), obstructed labor due to malposition of fetus (O64), delivery complicated by fetal stress (O68), umbilical cord complications (O69), perineal laceration (O70), and postpartum hemorrhage (O72). In addition, the likelihood of the delivery method being elective or emergency cesarean and whether there were any high-risk pregnancies that needed supervision (ICD-10: Z35) was also evaluated. Adverse pregnancy outcomes evaluated in this study included low-birthweight baby, preterm delivery, and stillbirth.

Statistical Analysis
--------------------

A log-binomial regression model---with a population-averaged generalized estimating equation modification accounting for correlation between pregnancies of the same survivor---was used to calculate relative risk (RR) estimates of pregnancy and labor complications by type of childhood cancer, site of radiotherapy treatment (none/cranial/abdominal/other), age at childhood cancer, and calendar period of treatment (\<1980/1980--1984/1985--1991). Abdominal radiotherapy was defined as any radiotherapy received for a tumor in the abdomen or pelvic volume. All models included the potential confounders maternal age and parity unless otherwise specified. Relative risks were also calculated for Wilms tumor survivors as these would have received some of the highest doses of abdominal irradiation and also comprise a sufficiently large group to consider separately. To determine whether survivors differed in their risk of developing pregnancy and labor complications from the general population independent of an effect of radiotherapy, survivors treated without radiotherapy were chosen for comparisons with the general population.

Although the completeness of HES ascertainment increased over calendar years, not all deliveries may have been recorded within HES, particularly before 2002 ([@djx056-B15],[@djx056-B16]). A recent exercise whereby HES delivery records from 2002 to 2010 were linked with the Office of National Statistics (ONS) birth registrations found that 96.8% of all births recorded by ONS were also recorded in HES, suggesting that---at least for the period 2002 to 2010---the majority of deliveries are captured by HES ([@djx056-B17]). To ascertain whether potential underreporting of deliveries and adverse pregnancy and labor outcomes in the years 1997 to 2001 could have potentially introduced bias, we conducted a sensitivity analysis by fitting HES calendar year (1997--2001 vs 2002--2012) as an interaction term in our model. Such an interaction term should detect whether there is statistically significant variation in the risk of developing a specific pregnancy or labor complication by HES calendar year.

For factors with multiple categories, a test for homogeneity of the relative risks across the levels of the factor was also performed, and *P*~heterogeneity~ was used to indicate the statistical significance of the overall test. All analyses were performed using Stata 14 (StataCorp, College Station, Texas) ([@djx056-B18]). Statistical significance was defined at a two-sided *P* value of less than .05.

Results
=======

Cohort Characteristics
----------------------

A total of 2783 singleton deliveries among 1712 female survivors of childhood cancer were available for analysis ([Table 1](#djx056-T1){ref-type="table"}). The mean maternal age at the delivery-related admission was 28.7 years (SD = 5.4 years). The majority of recorded deliveries were among survivors of leukemia (32.9%, n = 915), central nervous system tumor (12.1%, n = 336), and Wilms tumor (11.6%, n = 322). In terms of site of radiotherapy treatment, 205 (12.0%) survivors had received abdominal radiotherapy (of whom 127, 62.0%, were Wilms tumor survivors), 543 (31.7%) had received radiotherapy to the brain, 529 (30.9%) had not been treated with any radiotherapy, and 146 (8.5%) had received radiotherapy to sites other than the abdomen or brain. Table 1.Characteristics of female survivors with at least one recorded delivery episode in Hospital Episode Statistics (HES; n = 1712) and singleton pregnancies of female survivors recorded in HES (n = 2783)CharacteristicIndividuals (n = 1712) No. (%)Pregnancies (n = 2783) No. (%)Excluded pregnancies (n = 120)[\*](#tblfn1){ref-type="table-fn"} No. (%)Type of childhood cancer  Leukemia546 (31.9)915 (32.9)32 (26.7)  Hodgkin lymphoma93 (5.4)153 (5.5)11 (9.2)  Non-Hodgkin lymphoma69 (4.0)111 (4.0)5 (4.2)  CNS tumor218 (12.7)336 (12.1)19 (15.8)  Neuroblastoma85 (5.0)135 (4.9)5 (4.2)  NH-retinoblastoma89 (5.2)143 (5.1)3 (2.5)  H-retinoblastoma35 (2.0)58 (2.1)5 (4.2)  Wilms tumor199 (11.6)322 (11.6)14 (11.7)  Bone tumor92 (5.4)145 (5.2)5 (4.2)  Soft-tissue sarcoma112 (6.5)185 (6.6)6 (5.0)  Other174 (10.2)280 (10.1)15 (12.5)Type of radiotherapy  None529 (30.9)860 (30.9)44 (36.7)  Brain543 (31.7)901 (32.4)29 (24.2)  Other (nonbrain/abdominal)146 (8.5)231 (8.3)12 (10.0)  Abdominal205 (12.0)326 (11.7)9 (7.5)  Abdominal after:   Wilms tumor127 (7.4)207 (7.4)3 (2.5)   Hodgkin lymphoma19 (1.1)30 (1.1)2 (1.7)   Soft-tissue sarcoma16 (0.9)24 (0.9)1 (0.8)   Bone tumor15 (0.9)23 (0.8)1 (0.8)   Non-Hodgkin lymphoma9 (0.5)15 (0.5)1 (0.8)   Neuroblastoma7 (0.4)10 (0.4)0 (0.0)   Other12 (0.7)17 (0.6)1 (0.8)  Unknown289 (16.9)465 (16.7)26 (21.7)Wilms tumor  No radiotherapy59 (3.4)96 (3.4)4 (3.3)  Abdominal radiotherapy127 (7.4)207 (7.4)3 (2.5)  Unknown13 (0.8)19 (0.7)7 (5.8)Age at childhood cancer diagnosis, y  0--4802 (46.8)1315 (47.3)39 (32.5)  5--9481 (28.1)781 (28.1)49 (40.8)  10--14429 (25.1)687 (24.7)32 (26.7)Calendar year of childhood cancer  1955--196978 (4.6)102 (3.7)3 (2.5)  1970--1974175 (10.2)246 (8.8)13 (10.8)  1975--1979308 (18.0)500 (18.0)21 (17.5)  1980--1984465 (27.2)809 (29.1)42 (35.0)  1985--1991686 (40.1)1126 (40.5)41 (34.2)Maternal age, y  \<1832 (1.9)†33 (1.2)0 (0.0)  18--24467 (27.3)†636 (22.9)29 (24.2)  25--29532 (31.1)†873 (31.4)38 (31.7)  30--34457 (26.7)†818 (29.4)33 (27.5)  ≥35224 (13.1)†423 (15.2)20 (16.7)[^1][^2]

Hypertension, Diabetes Mellitus, and Anemia in Pregnancy
--------------------------------------------------------

The relative risk of developing hypertension complicating pregnancy was substantially elevated among Wilms tumor survivors treated with abdominal radiotherapy (RR = 3.29, 95% confidence interval \[CI\] = 2.29 to 4.71) vs those treated without radiotherapy ([Table 2](#djx056-T2){ref-type="table"}). Twenty-three point seven percent of all Wilms tumor survivors treated with abdominal radiotherapy experienced hypertension that complicated the pregnancy vs only 7.1% of all survivors not treated with radiotherapy and 6.0% of women in the general population. Wilms tumor survivors not treated with abdominal radiotherapy were, however, not at statistically significant risk of developing hypertension complicating pregnancy (RR = 1.36, 95% CI = 0.68 to 2.71). Other survivors (ie, non-Wilms tumor) treated with abdominal radiotherapy were not at statistically significant risk either (RR = 1.09, 95% CI = 0.52 to 2.28). Similar relative risks as reported above were observed when excluding preexisting hypertension (ICD10: O10-O11), that is, for gestational hypertension only ([Table 2](#djx056-T2){ref-type="table"}). Table 2.Relative risk of developing a hypertensive disorder, diabetes mellitus, or anemia in pregnancy among female survivors of childhood cancerCharacteristicMaternal disorders related to pregnancyOther obstetric conditionsHypertension complicating pregnancy[\*](#tblfn3){ref-type="table-fn"} ICD10: O10-O11, O13-O16Hypertension complicating pregnancy[\*](#tblfn3){ref-type="table-fn"} (excluding preexisting hypertension) ICD10:O13-O16Gestational diabetes mellitus[\*](#tblfn3){ref-type="table-fn"},† ICD10: O24.4Anemia complicating pregnancy[\*](#tblfn3){ref-type="table-fn"},‡ ICD10: O99.0No. (%)RR (95% CI)*P*§No. (%)RR (95% CI)*P*§No. (%)RR (95% CI)*P*§No. (%)RR (95% CI)*P*§General population1495 (6.0)1.00 (ref.)1013 (4.1)1.00 (ref.)390 (1.6)1.00 (ref.)1099 (4.4)1.00 (ref.)  Female survivors*‖*61 (7.1)1.23 (0.95 to 1.60).1140 (4.7)1.18 (0.85 to 1.65).3213 (1.5)0.91 (0.49 to 1.71).7234 (4.0)0.88 (0.58 to 1.29).52Type of childhood cancer  Leukemia81 (8.9)1.00 (ref.)51 (5.6)1.00 (ref.)18 (2.0)1.00 (ref.)52 (5.7)1.00 (ref.)  Hodgkin lymphoma10 (6.5)0.62 (0.30 to 1.25).186 (3.9)0.61 (0.23 to 1.58).315 (3.3)1.33 (0.46 to 3.90).6010 (6.5)1.12 (0.59 to 2.13).73  Non-Hodgkin lymphoma13 (11.7)1.18 (0.62 to 2.25).619 (8.1)1.34 (0.61 to 2.98).474 (3.6)1.64 (0.49 to 5.56).428 (7.2)1.18 (0.56 to 2.51).66  CNS tumor25 (7.4)0.83 (0.53 to 1.30).4115 (4.5)0.81 (0.45 to 1.45).474 (1.2)0.60 (0.21 to 1.74).3517 (5.1)0.86 (0.48 to 1.54).61  Neuroblastoma17 (12.6)1.41 (0.80 to 2.48).2413 (9.6)1.71 (0.90 to 3.23).102 (1.5)0.99 (0.23 to 4.32).994 (3.0)0.49 (0.18 to 1.32).16  NH-retinoblastoma6 (4.2)0.50 (0.22 to 1.14).102 (1.4)0.27 (0.07 to 1.11).074 (2.8)1.24 (0.37 to 4.13).733 (2.1)0.38 (0.12 to 1.18).09  H-retinoblastoma3 (5.2)0.66 (0.22 to 2.01).463 (5.2)1.05 (0.34 to 3.26).930 (0.0)------3 (5.2)0.94 (0.30 to 2.91).91  Wilms tumor61 (18.9)2.12 (1.52 to 2.97)\<.00144 (13.7)2.38 (1.56 to 3.64)\<.0018 (2.5)1.27 (0.49 to 3.25).6221 (6.5)1.15 (0.70 to 1.89).57  Bone tumor9 (6.2)0.64 (0.31 to 1.33).237 (4.8)0.76 (0.32 to 1.81).531 (0.7)0.39 (0.05 to 2.91).367 (4.8)0.82 (0.32 to 2.06).67  Soft-tissue sarcoma16 (8.6)0.93 (0.53 to 1.64).8012 (6.5)1.13 (0.58 to 2.18).725 (2.7)1.11 (0.30 to 4.01).8810 (5.4)0.95 (0.47 to 1.93).88  Other21 (7.5)0.85 (0.52 to 1.40).5414 (5.0)0.91 (0.49 to 1.67).765 (1.8)0.83 (0.30 to 2.34).738 (2.9)0.51 (0.24 to 1.06).07  *P*~heterogeneity~§\<.001\<.001.93.47Treated with radiotherapy  No61 (7.1)1.00 (ref.)40 (4.7)1.00 (ref.)13 (1.5)1.00 (ref.)34 (4.0)1.00 (ref.)  Brain82 (9.1)1.25 (0.89 to 1.76).2049 (5.4)1.17 (0.75 to 1.82).4919 (2.1)1.61 (0.72 to 3.59).2449 (5.4)1.39 (0.89 to 2.18).15  Other (nonbrain/abdominal)22 (9.5)1.28 (0.76 to 2.14).3618 (7.8)1.64 (0.89 to 3.02).115 (2.2)1.61 (0.55 to 4.67).385 (2.2)0.57 (0.22 to 1.44).23  Abdominal59 (18.1)2.43 (1.70 to 3.47)\<.00142 (12.9)2.69 (1.72 to 4.22)\<.00116 (4.9)3.35 (1.41 to 7.93).0127 (8.3)2.10 (1.27 to 3.46).004   Abdominal non-Wilms10 (8.4)1.09 (0.52 to 2.28).817 (5.9)1.17 (0.48 to 2.83).738 (6.7)4.27 (1.54 to 11.83).0111 (9.2)2.25 (1.13 to 4.49).02   Abdominal Wilms only49 (23.7)3.29 (2.29 to 4.71)\<.00135 (16.9)3.59 (2.27 to 5.68)\<.0018 (3.9)2.73 (1.00 to 7.62).0516 (7.7)2.00 (1.13 to 3.57).02  No radiotherapy Wilms only9 (9.4)1.36 (0.68 to 2.71).387 (7.3)1.60 (0.70 to 3.64).260 (0.0)------4 (4.2)1.05 (0.36 to 3.12).93  *P*~heterogeneity~§\<.001\<.001.23.01Age at diagnosis, y  0--4136 (10.3)1.00 (ref.)93 (7.1)1.00 (ref.)31 (2.4)1.00 (ref.)74 (5.6)1.00 (ref.)  5--970 (9.0)0.96 (0.69 to 1.34).8346 (5.9)0.86 (0.56 to 1.32).4813 (1.7)0.61 (0.28 to 1.34).2240 (5.1)0.75 (0.46 to 1.24).27  10--1456 (8.2)1.06 (0.68 to 1.64).7837 (5.4)1.03 (0.60 to 1.79).9112 (1.7)0.81 (0.36 to 1.80).6129 (4.2)0.67 (0.38 to 1.19).17  *P*~trend~§.85.94.54.15Decade of diagnosis  \<198086 (10.1)1.00 (ref.)54 (6.4)1.00 (ref.)14 (1.7)1.00 (ref.)49 (5.8)1.00 (ref.)  1980--198473 (9.0)1.00 (0.70 to 1.43).9950 (6.2)1.06 (0.67 to 1.67).8019 (2.3)1.53 (0.61 to 3.83).3641 (5.1)0.82 (0.50 to 1.36).44  1985--199192 (9.3)1.05 (0.66 to 1.66).8565 (6.6)1.16 (0.66 to 2.03).6019 (1.9)1.34 (0.49 to 3.64).5648 (4.8)0.76 (0.41 to 1.41).39  *P*~trend~§.84.59.66.41[^3][^4][^5][^6][^7]

Survivors treated with abdominal radiotherapy were at 3.35-fold (95% CI = 1.41 to 7.93) risk of gestational diabetes mellitus compared with survivors treated without radiotherapy ([Table 2](#djx056-T2){ref-type="table"}), and this relative risk was increased for both Wilms tumor (RR = 2.73, 95% CI = 1.00 to 7.62) and non-Wilms tumor (RR = 4.27, 95% CI = 1.54 to 11.83) survivors. Overall, 4.9% of all survivors treated with abdominal radiotherapy developed diabetes mellitus during pregnancy, whereas this was only 1.5% in all survivors not treated with radiotherapy and 1.6% in the general population.

The relative risk of having developed anemia that complicates pregnancy was statistically significantly elevated among survivors treated with abdominal radiotherapy compared with survivors treated without radiotherapy (RR = 2.10, 95% CI = 1.27 to 3.46) and elevated for both Wilms (RR = 2.00, 95% CI = 1.13 to 3.57) and non-Wilms tumor (RR = 2.25, 95% CI = 1.13 to 4.49) survivors ([Table 2](#djx056-T2){ref-type="table"}). Eight point three percent of all survivors treated with abdominal radiotherapy experienced a pregnancy that was complicated by anemia, compared with 4.0% of survivors treated without radiotherapy and 4.4% in the general population.

Maternal Care for Known or Suspected Disorder
---------------------------------------------

Prior treatment with radiotherapy did not affect the likelihood of receiving specific maternal care for a known or suspected malpresentation of the fetus (*P*~heterogeneity~ = .96), a uterine scar from previous surgery (*P*~heterogeneity~ = .14), fetal problems such as poor fetal growth (*P*~heterogeneity~ = .66), or a prolonged pregnancy (*P*~heterogeneity~ = .58) ([Table 3](#djx056-T3){ref-type="table"}). Previous treatment with radiotherapy to the brain was associated with a small increased risk of premature rupture of the membranes (RR = 1.49, 95% CI = 1.07 to 2.08). Table 3.Relative risk of receiving maternal care for problems relating to the fetus, amniotic cavity, and possible delivery problems among female survivors of childhood cancerCharacteristicMaternal care related to:Malpresentation of fetus[\*](#tblfn8){ref-type="table-fn"} ICD10: O32Uterine scar from previous surgery[\*](#tblfn8){ref-type="table-fn"},† ICD10: O34.2Fetal problems[\*](#tblfn8){ref-type="table-fn"},‡ ICD10: O36Premature rupture of membranes[\*](#tblfn8){ref-type="table-fn"} ICD10: O42Prolonged (post-term) pregnancy[\*](#tblfn8){ref-type="table-fn"},§,‖ ICD10: O48No. (%)RR (95% CI)*P*¶No. (%)RR (95%CI)*P*¶No. (%)RR (95% CI)*P*¶No. (%)RR (95% CI)*P*¶No. (%)RR (95% CI)*P*¶General population1058 (4.2)1.00 (ref.)1699 (6.8)1.00 (ref.)1431 (5.7)1.00 (ref.)1913 (7.7)1.00 (ref.)1349 (5.4)1.00 (ref.)  Female survivors*\#*41 (4.8)1.08 (0.78 to 1.62).4276 (8.8)1.23 (0.98 to 1.56).0953 (6.2)1.08 (0.82 to 1.41).6554 (6.3)0.83 (0.63 to 1.09).1550 (5.8)1.12 (0.82 to 1.49).50Type of childhood cancer  Leukemia47 (5.1)1.00 (ref.)86 (9.4)1.00 (ref.)67 (7.3)1.00 (ref.)81 (8.9)1.00 (ref.)66 (7.2)1.00 (ref.)  Hodgkin lymphoma9 (5.9)1.10 (0.50 to 2.45).8111 (7.2)0.53 (0.23 to 1.20).1311 (7.2)1.00 (0.50 to 2.01).9917 (11.1)1.17 (0.73 to 1.89).517 (4.6)0.59 (0.26 to 1.36).24  Non-Hodgkin lymphoma4 (3.6)0.66 (0.25 to 1.76).4113 (11.7)1.06 (0.59 to 1.92).847 (6.3)0.87 (0.38 to 2.01).7510 (9.0)0.98 (0.51 to 1.88).946 (5.4)0.74 (0.34 to 1.64).44  CNS tumor19 (5.7)1.04 (0.60 to 1.78).8934 (10.1)1.10 (0.75 to 1.62).6220 (6.0)0.81 (0.48 to 1.37).4324 (7.1)0.75 (0.49 to 1.15).1922 (6.5)0.84 (0.54 to 1.44).48  Neuroblastoma4 (3.0)0.62 (0.22 to 1.69).3511 (8.1)0.98 (0.51 to 1.86).9515 (11.1)1.48 (0.84 to 2.61).1812 (8.9)1.04 (0.57 to 1.90).912 (1.5)0.16 (0.06 to 0.90).04  NH-retinoblastoma4 (2.8)0.50 (0.18 to 1.35).1710 (7.0)0.80 (0.43 to 1.46).466 (4.2)0.59 (0.26 to 1.33).2110 (7.0)0.76 (0.41 to 1.43).4012 (8.4)1.13 (0.61 to 2.12).70  H-retinoblastoma4 (6.9)1.43 (0.54 to 3.81).472 (3.4)0.36 (0.05 to 2.51).302 (3.4)0.42 (0.11 to 1.60).203 (5.2)0.56 (0.19 to 1.64).295 (8.6)1.23 (0.53 to 2.84).65  Wilms tumor18 (5.6)1.11 (0.65 to 1.89).7029 (9.0)0.97 (0.63 to 1.50).8930 (9.3)1.35 (0.86 to 2.10).1923 (7.1)0.78 (0.50 to 1.23).2911 (3.4)0.52 (0.28 to 0.94).02  Bone tumor6 (4.1)0.81 (0.35 to 1.86).6212 (8.3)0.96 (0.54 to 1.69).895 (3.4)0.49 (0.20 to 1.20).1212 (8.3)0.90 (0.49 to 1.65).728 (5.5)0.74 (0.34 to 1.64).45  Soft-tissue sarcoma9 (4.9)0.94 (0.44 to 2.01).8717 (9.2)0.86 (0.51 to 1.45).5713 (7.0)0.95 (0.54 to 1.68).8712 (6.5)0.70 (0.37 to 1.33).2715 (8.1)1.04 (0.60 to 1.94).88  Other13 (4.6)0.88 (0.46 to 1.66).6927 (9.6)0.92 (0.58 to 1.44).7112 (4.3)0.61 (0.33 to 1.13).1218 (6.4)0.70 (0.42 to 1.16).1611 (3.9)0.48 (0.25 to 0.98).04  *P*~heterogeneity~¶.89.90.15.72.12Treated with radiotherapy  No41 (4.8)1.00 (ref.)76 (8.8)1.00 (ref.)53 (6.2)1.00 (ref.)54 (6.3)1.00 (ref.)50 (5.8)1.00 (ref.)  Brain48 (5.3)1.12 (0.73 to 1.72).6086 (9.5)1.15 (0.84 to 1.57).3870 (7.8)1.24 (0.86 to 1.79).2582 (9.1)1.49 (1.07 to 2.08).0264 (7.1)1.19 (0.82 to 1.76).30  Other (nonbrain/abdominal)12 (5.2)1.05 (0.52 to 2.10).9016 (6.9)0.66 (0.36 to 1.18).1616 (6.9)1.13 (0.65 to 1.97).6719 (8.2)1.27 (0.77 to 2.09).3514 (6.1)0.85 (0.46 to 1.75).77  Abdominal17 (5.2)1.07 (0.62 to 1.85).8238 (11.7)1.31 (0.88 to 1.93).1824 (7.4)1.26 (0.78 to 2.03).3521 (6.4)1.01 (0.61 to 1.68).9618 (5.5)0.94 (0.54 to 1.64).79   Abdominal non-Wilms4 (3.4)0.66 (0.24 to 1.81).4215 (12.6)1.41 (0.83 to 2.40).216 (5.0)0.80 (0.32 to 2.04).659 (7.6)1.18 (0.56 to 2.45).678 (6.7)1.06 (0.54 to 2.29).86   Abdominal Wilms only13 (6.3)1.33 (0.72 to 2.43).3623 (11.1)1.26 (0.79 to 2.02).3318 (8.7)1.47 (0.88 to 2.47).1412 (5.8)0.93 (0.51 to 1.70).8310 (4.8)0.84 (0.44 to 1.64).58  No radiotherapy Wilms only5 (5.2)1.15 (0.46 to 2.91).766 (6.3)0.82 (0.32 to 2.14).699 (9.4)1.68 (0.75 to 3.79).218 (8.3)1.47 (0.69 to 3.15).321 (1.0)0.19 (0.03 to 1.36).10  *P*~heterogeneity~**¶**.96.14.66.09.58Age at diagnosis, y  0--465 (4.9)1.00 (ref.)114 (8.7)1.00 (ref.)100 (7.6)1.00 (ref.)100 (7.6)1.00 (ref.)71 (6.3)1.00 (ref.)  5--937 (4.7)0.88 (0.54 to 1.43).6169 (8.8)0.89 (0.62 to 1.27).5156 (7.2)1.07 (0.72 to 1.60).7371 (9.1)1.29 (0.91 to 1.83).1548 (7.0)1.24 (0.78 to 1.97).36  10--1435 (5.1)0.72 (0.39 to 1.33).3069 (10.0)0.92 (0.62 to 1.37).6732 (4.7)0.78 (0.47 to 1.30).3551 (7.4)0.92 (0.58 to 1.46).7441 (7.0)1.32 (0.77 to 2.27).32  *P*~trend~**¶**.30.63.46.99.29Decade of diagnosis  \<198049 (5.8)1.00 (ref.)112 (13.2)1.00 (ref.)58 (6.8)1.00 (ref.)58 (6.8)1.00 (ref.)46 (6.7)1.00 (ref.)  1980--198439 (4.8)0.93 (0.56 to 1.55).7874 (9.1)0.72 (0.51 to 1.02).0754 (6.7)1.07 (0.67 to 1.73).7765 (8.0)1.23 (0.82 to 1.84).3259 (8.4)1.34 (0.82 to 2.20).24  1985--199141 (4.1)0.87 (0.46 to 1.64).6657 (5.8)0.52 (0.33 to 0.81)\<.00167 (6.8)1.10 (0.65 to 1.88).7291 (9.2)1.35 (0.85 to 2.16).2153 (6.0)0.97 (0.53 to 1.80).93  *P*~trend~**¶**.66.004.72.22.76[^8][^9][^10][^11][^12][^13][^14]

Complications of Labor and Delivery
-----------------------------------

No statistically significant associations could be detected between any of the factors under study and the labor complications: abnormalities of forces of labor, long labor, obstructed labor, umbilical cord complications, delivery complicated by fetal stress (except for Wilms tumor survivors having a reduced risk of a delivery being complicated by fetal stress (RR = 0.73, 95% CI = 0.57 to 0.94) ([Table 4](#djx056-T4){ref-type="table"})), perineal laceration, or postpartum hemorrhage ([Table 5](#djx056-T5){ref-type="table"}). Table 4.Relative risk of developing specific complications of labor and delivery among female survivors of childhood cancerCharacteristicComplications of labor and deliveryAbnormalities of forces of labor[\*](#tblfn15){ref-type="table-fn"},†,‡ ICD10: O62Long labor‡,§,‖ ICD10: O63Obstructed labor[\*](#tblfn15){ref-type="table-fn"},‡ ICD10: O64-O66Delivery complicated by fetal stress[\*](#tblfn15){ref-type="table-fn"},¶ ICD10: O68Umbilical cord complications[\*](#tblfn15){ref-type="table-fn"} ICD10: O69No. (%)RR (95% CI)*P*\#No. (%)RR (95% CI)*P*\#No. (%)RR (95% CI)*P*\#No. (%)RR (95% CI)*P*\#No. (%)RR (95% CI)*P*\#General population720 (3.2)1.00 (ref.)2730 (12.0)1.00 (ref.)1007 (4.4)1.00 (ref.)5370 (23.7)1.00 (ref.)621 (2.7)1.00 (ref.)  Female survivors[\*\*](#tblfn22){ref-type="table-fn"}25 (3.3)1.14 (0.74 to 1.58).75104 (13.8)1.21 (0.98 to 1.44).0934 (4.5)1.04 (0.72 to 1.54).83191 (25.4)1.10 (0.96 to 1.24).1427 (3.6)1.28 (0.86 to 1.88).15Type of childhood cancer  Leukemia21 (2.6)1.00 (ref.)110 (13.8)1.00 (ref.)47 (5.9)1.00 (ref.)227 (28.4)1.00 (ref.)29 (3.6)1.00 (ref.)  Hodgkin lymphoma10 (7.2)2.25 (0.98 to 5.16).0626 (18.7)1.22 (0.83 to 1.79).327 (5.0)0.85 (0.39 to 1.84).6731 (22.3)0.73 (0.52 to 1.02).066 (4.3)1.21 (0.52 to 2.83).66  Non-Hodgkin lymphoma1 (1.1)0.36 (0.05 to 2.63).3212 (12.8)0.85 (0.48 to 1.52).593 (3.2)0.53 (0.17 to 1.67).2829 (30.9)1.02 (0.73 to 1.42).922 (2.1)0.60 (0.14 to 2.52).49  CNS tumor16 (5.7)1.93 (0.99 to 3.77).0540 (14.3)0.93 (0.67 to 1.30).6816 (5.7)0.95 (0.54 to 1.65).8567 (24.0)0.78 (0.62 to 1.00).0512 (4.3)1.20 (0.62 to 2.34).59  Neuroblastoma3 (2.7)1.06 (0.32 to 3.50).9217 (15.2)1.06 (0.67 to 1.67).801 (0.9)0.15 (0.02 to 1.04).0529 (25.9)0.92 (0.66 to 1.29).641 (0.9)0.25 (0.03 to 1.84).17  NH-retinoblastoma6 (4.6)1.60 (0.66 to 3.92).3015 (11.5)0.76 (0.44 to 1.31).328 (6.1)1.06 (0.51 to 2.18).8734 (26.0)0.86 (0.61 to 1.21).397 (5.3)1.50 (0.67 to 3.36).33  H-retinoblastoma1 (1.9)0.67 (0.09 to 4.88).693 (5.8)0.43 (0.14 to 1.29).130 (0.0)------8 (15.4)0.56 (0.30 to 1.03).061 (1.9)0.53 (0.08 to 3.80).53  Wilms tumor6 (2.2)0.83 (0.34 to 2.05).6929 (10.9)0.76 (0.51 to 1.14).1811 (4.1)0.71 (0.37 to 1.35).2955 (20.6)0.73 (0.57 to 0.94).0111 (4.1)1.14 (0.58 to 2.25).70  Bone tumor0 (0.0)------22 (19.0)1.29 (0.87 to 1.92).216 (5.2)0.85 (0.37 to 1.95).7136 (31.0)1.09 (0.82 to 1.45).535 (4.3)1.19 (0.48 to 2.97).70  Soft-tissue sarcoma3 (1.9)0.66 (0.20 to 2.16).4919 (11.9)0.81 (0.50 to 1.30).3712 (7.5)1.30 (0.71 to 2.39).3946 (28.9)0.95 (0.72 to 1.26).713 (1.9)0.53 (0.16 to 1.69).28  Other9 (3.7)1.28 (0.59 to 2.74).5343 (17.6)1.23 (0.89 to 1.69).219 (3.7)0.63 (0.29 to 1.34).2357 (23.3)0.81 (0.63 to 1.04).096 (2.4)0.68 (0.29 to 1.60).38  *P*~heterogeneity~**\#**.28.24.47.09.69Treated with radiotherapy  No25 (3.3)1.00 (ref.)104 (13.8)1.00 (ref.)34 (4.5)1.00 (ref.)191 (25.4)1.00 (ref.)27 (3.6)1.00 (ref.)  Brain20 (2.6)0.86 (0.48 to 1.55).61100 (13.0)1.01 (0.78 to 1.31).9445 (5.8)1.30 (0.83 to 2.03).26212 (27.5)1.11 (0.94 to 1.31).2428 (3.6)0.99 (0.59 to 1.67).98  Other (nonbrain/abdominal)8 (4.0)1.04 (0.45 to 2.41).9333 (16.5)1.08 (0.74 to 1.57).698 (4.0)0.86 (0.41 to 1.83).7053 (26.5)0.97 (0.74 to 1.27).8211 (5.5)1.56 (0.79 to 3.10).20  Abdominal9 (3.5)0.98 (0.44 to 2.17).9633 (12.7)0.93 (0.64 to 1.33).6810 (3.8)0.85 (0.43 to 1.69).6456 (21.5)0.84 (0.65 to 1.09).198 (3.1)0.86 (0.40 to 1.86).71   Abdominal non-Wilms5 (5.2)1.37 (0.47 to 4.00).5619 (19.8)1.35 (0.87 to 2.09).186 (6.3)1.38 (0.60 to 3.19).4427 (28.1)1.01 (0.71 to 1.43).962 (2.1)0.56 (0.14 to 2.30).42   Abdominal Wilms only4 (2.4)0.74 (0.26 to 2.10).5814 (8.5)0.66 (0.39 to 1.11).124 (2.4)0.54 (0.19 to 1.48).2329 (17.7)0.72 (0.51 to 1.03).076 (3.7)1.01 (0.43 to 2.39).98  No radiotherapy Wilms only2 (2.4)0.81 (0.20 to 3.23).7610 (11.9)0.88 (0.44 to 1.77).733 (3.6)0.76 (0.23 to 2.51).6517 (20.2)0.90 (0.59 to 1.37).614 (4.8)1.46 (0.51 to 4.15).48  *P*~heterogeneity~**\#**.96.93.46.18.51Age at diagnosis, y  0--427 (2.4)1.00 (ref.)146 (13.0)1.00 (ref.)47 (4.2)1.00 (ref.)293 (26.0)1.00 (ref.)36 (3.2)1.00 (ref.)  5--924 (3.5)1.29 (0.67 to 2.50).4593 (13.6)0.94 (0.71 to 1.25).6736 (5.3)1.08 (0.65 to 1.79).76167 (24.4)0.89 (0.73 to 1.09).2724 (3.5)0.90 (0.49 to 1.62).72  10--1425 (4.3)1.77 (0.82 to 3.85).1596 (16.5)0.90 (0.64 to 1.27).5636 (6.2)1.78 (1.05 to 3.04).03159 (27.3)1.02 (0.80 to 1.28).8923 (4.0)1.21 (0.62 to 2.34).57  *P*~trend~**\#**.15.55.05.96.63Decade of diagnosis  \<198026 (3.8)1.00 (ref.)108 (15.7)1.00 (ref.)29 (4.2)1.00 (ref.)190 (27.7)1.00 (ref.)31 (4.5)1.00 (ref.)  1980--198420 (2.8)1.12 (0.56 to 2.26).7489 (12.6)0.77 (0.57 to 1.03).0835 (5.0)1.27 (0.72 to 2.23).41181 (25.6)0.97 (0.78 to 1.21).8026 (3.7)1.21 (0.62 to 2.36).58  1985--199127 (3.1)1.72 (0.79 to 3.76).17119 (13.5)0.76 (0.53 to 1.08).1244 (5.0)1.26 (0.66 to 2.41).49215 (24.3)0.87 (0.67 to 1.14).3222 (2.5)1.21 (0.53 to 2.76).66  *P*~trend~**\#**.16.15.54.29.66[^15][^16][^17][^18][^19][^20][^21][^22]Table 5.Relative risk of developing specific complications of labor and delivery among female survivors of childhood cancerCharacteristicComplications of labor and deliveryDeliverySupervision of high-risk pregnancy[\*](#tblfn23){ref-type="table-fn"} ICD10: Z35Perineal laceration[\*](#tblfn23){ref-type="table-fn"},† ICD10: O70Postpartum hemorrhage[\*](#tblfn23){ref-type="table-fn"} ICD10: O72Elective cesarean section[\*](#tblfn23){ref-type="table-fn"},†Emergency cesarean section[\*](#tblfn23){ref-type="table-fn"},†No. (%)RR (95% CI)*P*‡No. (%)RR (95% CI)*P*‡No. (%)RR (95% CI)*P*‡No. (%)RR (95% CI)*P*‡No. (%)RR (95% CI)*P*‡General population9229 (40.7)1.00 (ref.)2179 (8.7)1.00 (ref.)2249 (10.4)1.00 (ref.)3174 (14.0)1.00 (ref.)999 (4.0)1.00 (ref.)  Female survivors§313 (41.7)0.99 (0.89 to 1.10).7582 (9.5)1.08 (0.93 to 1.28).46109 (14.7)1.39 (1.16 to 1.70)\<.001119 (15.8)1.08 (0.91 to 1.27).2141 (4.8)1.19 (0.85 to 1.64).32Type of childhood cancer  Leukemia307 (38.4)1.00 (ref.)93 (10.2)1.00 (ref.)116 (15.2)1.00 (ref.)148 (18.6)1.00 (ref.)34 (3.7)1.00 (ref.)  Hodgkin lymphoma63 (45.3)1.16 (0.94 to 1.43).1718 (11.8)1.03 (0.62 to 1.69).9214 (10.3)0.59 (0.32 to 1.08).0917 (12.2)0.59 (0.36 to 0.97).048 (5.2)0.97 (0.44 to 2.18).95  Non-Hodgkin lymphoma30 (31.9)0.81 (0.59 to 1.11).1910 (9.0)0.79 (0.37 to 1.69).5517 (18.7)1.09 (0.64 to 1.84).7520 (21.3)1.03 (0.67 to 1.60).884 (3.6)0.88 (0.33 to 2.39).80  CNS tumor109 (39.1)1.03 (0.86 to 1.24).7933 (9.8)0.87 (0.59 to 1.28).4757 (20.1)1.22 (0.90 to 1.65).2051 (18.3)0.90 (0.67 to 1.22).5112 (3.6)0.77 (0.40 to 1.47).43  Neuroblastoma43 (38.4)1.04 (0.80 to 1.34).8017 (12.6)1.27 (0.75 to 2.16).3723 (18.7)1.20 (0.74 to 1.96).4612 (10.7)0.64 (0.37 to 1.11).115 (3.7)1.04 (0.39 to 2.72).94  NH-retinoblastoma53 (40.5)1.09 (0.86 to 1.39).5014 (9.8)0.89 (0.52 to 1.53).6812 (9.8)0.71 (0.41 to 1.22).2121 (16.0)0.78 (0.50 to 1.21).267 (4.9)0.93 (0.41 to 2.12).86  H-retinoblastoma26 (50.0)1.28 (0.88 to 1.86).206 (10.3)1.00 (0.46 to 2.17).996 (11.5)0.77 (0.33 to 1.83).556 (11.5)0.68 (0.31 to 1.46).321 (1.7)0.37 (0.05 to 2.72).33  Wilms tumor102 (38.2)0.99 (0.81 to 1.21).9141 (12.7)1.23 (0.86 to 1.76).2655 (20.0)1.23 (0.88 to 1.73).2247 (17.6)0.97 (0.71 to 1.31).8316 (5.0)1.18 (0.62 to 2.26).61  Bone tumor46 (39.7)1.01 (0.78 to 1.30).9610 (6.9)0.63 (0.34 to 1.17).1429 (22.5)1.52 (1.05 to 2.20).0316 (13.8)0.77 (0.47 to 1.26).305 (3.4)0.86 (0.35 to 2.13).75  Soft-tissue sarcoma52 (32.7)0.85 (0.65 to 1.11).2118 (9.7)0.87 (0.54 to 1.42).5826 (17.2)1.07 (0.70 to 1.63).7633 (20.9)1.04 (0.73 to 1.50).818 (4.3)0.89 (0.40 to 1.99).78  Other95 (38.8)1.00 (0.82 to 1.21).9321 (7.5)0.69 (0.45 to 1.08).1035 (14.7)0.87 (0.58 to 1.29).4842 (17.1)0.89 (0.64 to 1.24).4814 (5.0)1.12 (0.60 to 2.09).72  *P*~heterogeneity~‡.59.46.10.50.99Treated with radiotherapy  No313 (41.7)1.00 (ref.)82 (9.5)1.00 (ref.)109 (14.7)1.00 (ref.)119 (15.8)1.00 (ref.)41 (4.8)1.00 (ref.)  Brain296 (38.3)0.91 (0.80 to 1.05).2193 (10.3)1.14 (0.85 to 1.53).37129 (17.0)1.15 (0.90 to 1.49).27138 (17.9)1.21 (0.95 to 1.53).1232 (3.6)0.88 (0.55 to 1.40).58  Other (nonbrain/abdominal)78 (39.0)0.94 (0.76 to 1.15).5523 (10.0)0.98 (0.62 to 1.55).9331 (15.7)0.90 (0.59 to 1.37).6333 (16.5)0.97 (0.67 to 1.40).8712 (5.2)0.95 (0.49 to 1.84).88  Abdominal97 (37.3)0.88 (0.72 to 1.07).2041 (12.6)1.33 (0.93 to 1.89).1266 (24.4)1.46 (1.07 to 1.99).0256 (21.5)1.35 (1.00 to 1.83).0517 (5.2)1.04 (0.58 to 1.87).90   Abdominal non-Wilms35 (36.5)0.83 (0.61 to 1.13).2315 (12.6)1.25 (0.75 to 2.07).3923 (24.0)1.36 (0.87 to 2.13).1823 (24.0)1.36 (0.87 to 2.11).176 (5.0)0.82 (0.33 to 2.07).68   Abdominal Wilms only62 (37.8)0.90 (0.70 to 1.14).3726 (12.6)1.37 (0.89 to 2.10).1543 (24.7)1.46 (1.01 to 2.11).0533 (20.1)1.32 (0.92 to 1.89).1311 (5.3)1.16 (0.58 to 2.33).68  No radiotherapy Wilms only34 (40.5)0.98 (0.71 to 1.35).9011 (11.5)1.37 (0.74 to 2.53).3112 (14.1)1.10 (0.57 to 2.12).7811 (13.1)1.06 (0.59 to 1.90).855 (5.2)1.39 (0.43 to 4.50).58  *P*~heterogeneity~‡.49.42.07.14.94Age at diagnosis, y  0--4427 (37.9)1.00 (ref.)132 (10.0)1.00 (ref.)189 (16.8)1.00 (ref.)1.00 (ref.)51 (3.9)1.00 (ref.)  5--9277 (40.4)1.01 (0.86 to 1.18).9383 (10.6)1.13 (0.81 to 1.58).4796 (14.4)0.79 (0.60 to 1.05).11111 (16.3)0.92 (0.70 to 1.21).5721 (2.7)0.69 (0.38 to 1.25).22  10--14220 (37.8)0.96 (0.80 to 1.16).6966 (9.6)1.08 (0.71 to 1.63).73105 (18.3)0.85 (0.61 to 1.19).35113 (19.4)1.15 (0.84 to 1.56).3642 (6.1)1.30 (0.78 to 2.17).31  *P*~trend~‡.73.65.26.46.35Decade of diagnosis  \<1980276 (40.2)1.00 (ref.)91 (10.7)1.00 (ref.)162 (22.3)1.00 (ref.)120 (17.5)1.00 (ref.)45 (5.3)1.00 (ref.)  1980--1984277 (39.2)1.03 (0.87 to 1.23).7282 (10.1)0.89 (0.63 to 1.27).52103 (15.1)0.70 (0.52 to 0.94).02127 (18.0)1.12 (0.84 to 1.50).4338 (4.7)1.35 (0.78 to 2.32).28  1985--1991333 (37.7)1.06 (0.87 to 1.31).5597 (9.8)0.88 (0.59 to 1.34).56108 (12.7)0.58 (0.40 to 0.83)\<.001140 (15.9)0.92 (0.64 to 1.31).6430 (3.0)1.21 (0.65 to 2.26).54  *P*~trend~‡.54.59.004.52.52[^23][^24][^25][^26]

Cesarean Delivery and Supervision High-Risk Pregnancy
-----------------------------------------------------

Compared with the general population, survivors treated without radiotherapy were 39% more likely to opt for an elective cesarean (RR = 1.39, 95% CI = 1.16 to 1.70). Particularly survivors of a bone tumor (RR = 1.52, 95% CI = 1.05 to 2.20) and those treated with abdominal radiotherapy (RR = 1.46, 95% CI = 1.07 to 1.99) ([Table 5](#djx056-T5){ref-type="table"}) were more likely to opt for a cesarean. Survivors treated longer ago were more likely to undergo an elective cesarean than more recently treated survivors (22.3% before 1980 vs 12.7% in 1985 to 1991, *P*~trend~ = .004). The risk of an emergency cesarean was not elevated among survivors compared with the general population (*P* = .21), although survivors of Hodgkin lymphoma appeared to be at reduced risk (RR = 0.59, 95% CI = 0.36 to 0.97). Pregnancies in survivors treated with abdominal radiotherapy were not identified as high-risk pregnancies requiring greater supervision than pregnancies in survivors treated without radiotherapy (RR = 1.04, 95% CI = 0.58 to 1.87).

Adverse Pregnancy Outcomes
--------------------------

Wilms tumor survivors treated with abdominal radiotherapy were at threefold risk of delivering offspring with a low birthweight compared with survivors treated without radiotherapy (RR = 2.85, 95% CI = 1.79 to 4.48) ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}, available online). The RR for preterm delivery was also statistically significantly increased for Wilms tumor survivors (RR = 1.89, 95% CI = 1.30 to 2.74). Only 19 hospital admissions were related to a stillbirth, and no stillbirths were recorded among women treated with abdominal radiotherapy.

Sensitivity Analysis by HES Calendar Year
-----------------------------------------

No statistically significant variation was found in the relative risk of developing a pregnancy or labor complication by HES calendar year ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}, available online), suggesting that if there was potential underreporting of any pregnancy or labor outcomes before HES year 2002, the effect would have been minimal.

Discussion
==========

To our knowledge, this is the largest study investigating the risks of pregnancy and labor complications in childhood cancer survivors. This study shows that treatment with abdominal radiotherapy increases the risk of developing hypertension complicating pregnancy in Wilms tumor survivors, as well as diabetes mellitus and anemia complicating pregnancy in all survivors. In addition, female survivors as a whole are more likely to opt for an elective cesarean than the general population. Our results of increased risks of preterm delivery and babies born with low birthweight among female survivors of childhood cancer treated with abdominal radiotherapy concur with previously reported data ([@djx056-B4]).

In this study, hypertensive disorders complicated 23.7% of all pregnancies among Wilms tumor survivors treated with abdomino-pelvic radiotherapy. Consistent with these findings, Green et al. ([@djx056-B13]) reported that 23.7% of all pregnancies among Wilms tumor survivors treated with irradiation were complicated by hypertension. There is a possibility that the risk of hypertension complicating pregnancy may be related to a previous nephrectomy rather than actual abdominal radiotherapy; however, because the vast majority of Wilms tumor survivors would have undergone a nephrectomy ([@djx056-B19],[@djx056-B20]), the risks should then, in theory, also be increased among those Wilms tumor survivors not treated with radiotherapy. However, this was not supported by our data---only 9.4% of Wilms tumor survivors not treated with abdominal radiotherapy developed hypertension complicating pregnancy; not statistically significantly different than that observed in the general population (6.0%) or than other survivors not treated with radiotherapy (7.1%).

The exact biological mechanism explaining the risk of hypertension and anemia complicating pregnancy after abdominal radiotherapy is poorly understood. Hypertension, anemia, and varying degrees of chronic glomerular impairment are well documented features of chronic radiation-induced renal injury, which may also reduce a survivor's reserve against future renal stresses. Statistically significant glomerular impairment has been reported in 25% to 56% of children receiving renal doses of 12 to 24 Gy ([@djx056-B21]). It is plausible that hypertension and anemia may be recognized for the first time during pregnancy in some female survivors with less severe degrees of chronic radiation-induced renal damage as a result of the greater physiological stresses and increased medical surveillance during pregnancy.

To our knowledge, this is the first study to report an elevated risk of developing diabetes in pregnancy among survivors treated with abdominal radiotherapy. A linked cancer-birth registry analysis from four US centers ([@djx056-B8]) showed in an exploratory analysis that female bone cancer survivors were at risk of diabetes during pregnancy (RR = 4.92, 95% CI = 1.60 to 15.13), but this was based on small observed numbers. Other studies have found that survivors of childhood cancer treated with abdominal radiation are at risk of developing diabetes ([@djx056-B22]), but not specifically during pregnancy. The mechanism for developing diabetes mellitus is unclear but may relate to a radiation-induced effect on the pancreas, perhaps causing inflammation and fibrosis, which may reduce subsequent insulin secretion from the islet cells.

In this study, survivors were more likely to opt for an elective cesarean than the general population. In a recent smaller study, Melin et al. ([@djx056-B26]) observed a 50% increased odds among 456 survivors of childhood cancer for undergoing a cesarean delivery compared with siblings which is consistent with our findings. It is not clear why survivors are more likely to opt for an elective cesarean, but it could be indicative of the obstetrician aiming to reduce any theoretical risk that a vaginal delivery might have. For example, survivors previously exposed to treatment modalities known to be associated with cardiomyopathy (eg, chest irradiation and high-dose cumulative doses of anthracycline) ([@djx056-B27]) might have opted for a cesarean delivery to decrease the potential risk relating to cardiomyopathy during labor and puerperium.

Several potential limitations should be considered. First, large-scale linkage exercises may suffer from inaccuracies with regard to linking the correct patient to the corresponding health records. However, because linkage of the BCCSS cohort with HES was done using NHS number, date of birth, and postcode of each patient, such inaccuracies in linkage are likely to be minimal. Lack of detailed treatment exposure, such as administered chemotherapy and radiation treatment charts, did not allow for conducting detailed dose-response analyses. However, we did consider Wilms tumor survivors separately who, if treated with radiotherapy, would have received one of the highest doses of radiation to the abdomen of all childhood cancer survivors. Evaluation of potential confounding of the association between abdominal irradiation and specific pregnancy and labor complications by chemotherapy was also not possible. Investigation of pregnancy and labor complications by detailed treatment exposure would require a nested case-control study. Last, we acknowledge that information on site of radiotherapy was missing for 16.9% of all survivors.

A major strength of the current study is the population-based design, which overcomes a variety of potential limitations including the issue of selection bias related to ascertainment of survivors of childhood cancer into the cohort. Hospital-based studies are probably more likely to include those survivors who were treated more intensely, and any absolute risk estimates of adverse late effects---including pregnancy outcomes---are therefore more likely to be overestimated than within a population-based study. It also provided us with the opportunity to compare the risks of pregnancy and labor outcomes with the general population in an entirely population-based way. Additionally, record linkage of our cohort with the population-based HES provides ascertainment of pregnancy and labor outcomes in a systematic way, unlike studies that ascertain adverse outcomes through either (postal) questionnaires or hospital records, which may suffer from nonresponse or selection bias, respectively.

It has previously been shown that uterine damage, manifested by impaired growth and blood flow, is a likely consequence of abdomino-pelvic irradiation ([@djx056-B12],[@djx056-B28],[@djx056-B29]) and that uterine volume correlates with age at irradiation ([@djx056-B30]). Exposure of the pelvis to radiation is associated with risk of miscarriage, delivering prematurely, and low-birthweight offspring, and in this study we have shown further evidence that there is a risk of hypertension complicating pregnancy in Wilms tumor survivors, and diabetes mellitus and anemia complicating pregnancy in all survivors who have received abdominal radiotherapy. Although survivors treated with abdominal radiotherapy were more likely to opt for an elective cesarean, the risks of specific complications during labor were not statistically significantly increased, and there is thus no evidence base for suggesting that an elective cesarean should be the optimum mode of delivery in survivors of childhood cancer treated with abdominal radiotherapy.

In conclusion, the results of this study into pregnancy and labor complications among female survivors of childhood cancer show that treatment with abdominal radiotherapy increases the risk of developing hypertension complicating pregnancy in Wilms tumor survivors, and diabetes mellitus and anemia complicating pregnancy in all survivors. These patients may require extra vigilance during pregnancy.
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[^1]: Home deliveries and births in private hospitals (n = 35), as well as pregnancies that resulted in a multiple birth (n = 85), were excluded. CNS = central nervous system; H = heritable; HES = Hospital Episode Statistics; NH = nonheritable.

[^2]: Relates to first recorded delivery episode.

[^3]: Adjusted for maternal age and parity. CNS = central nervous system; H = heritable; ICD = *International Classification of Diseases*, version 10; NH = nonheritable; RR = relative risk.

[^4]: Excludes preexisting diabetes mellitus (ICD 10: O24.0-O24.3) and unspecified whether preexisting or gestational diabetes (ICD 10: O24.9).

[^5]: Anemia complicating pregnancy, childbirth, and the puerperium.

[^6]: *P* value based on two-sided Wald test.

[^7]: Relates to all female survivors not treated with any radiotherapy.

[^8]: Adjusted for maternal age and parity. CNS = central nervous system; H = heritable; ICD = *International Classification of Diseases*, version 10; NH = nonheritable; RR = relative risk.

[^9]: Includes maternal care due to scar previous cesarean section.

[^10]: Includes maternal care for rhesus isoimmunization, maternal care for poor fetal growth, maternal care for excessive fetal growth.

[^11]: Deliveries via elective cesarean section excluded.

[^12]: Pregnancies that progressed beyond 42 weeks of gestation.

[^13]: *P* values were calculated using a two-sided Wald's test.

[^14]: Relates to all female survivors not treated with any radiotherapy.

[^15]: Adjusted for maternal age and parity. CNS = central nervous system; H = heritable; ICD = *International Classification of Diseases*, version 10; NH = nonheritable; RR = relative risk.

[^16]: For example, primary inadequate contractions; secondary uterine inertia; precipitate labor; hypertonic, incoordinate, and prolonged uterine contractions.

[^17]: Deliveries via elective cesarean section excluded.

[^18]: Long labor includes: prolonged first stage (ICD10: O63.0), prolonged second stage (ICD10: O63.1), and prolonged labor not otherwise specified (ICD10: O63.9).

[^19]: Adjusted for: maternal age, parity, birthweight, and gestational age.

[^20]: For example, labor and delivery complicated by fetal heart rate anomaly, meconium in amniotic fluid, or other evidence of fetal stress.

[^21]: *P* values were calculated using a two-sided Wald test.

[^22]: Relates to all female survivors not treated with any radiotherapy

[^23]: Adjusted for maternal age and parity. CNS = central nervous system; H = heritable; ICD = *International Classification of Diseases*, version 10; NH = nonheritable; RR = relative risk.

[^24]: Compared with vaginal delivery.

[^25]: *P* value based on two-sided Wald test.

[^26]: Relates to all female survivors not treated with any radiotherapy.
